Leadership Seminar: Addressing Infectious Diseases Challenges – 15th Nov

One NucleusInfectious Diseases is a vast therapeutic area. Some would claim the most ancient and still in 2017, one of the top healthcare priorities worldwide.

The figures speak for themselves, anti-microbial resistance itself may be responsible for 10 million deaths per year worldwide by 2050, having a 3.5% adverse impact on GDP and costing $ 100 trillion to the world economy in the same timescale.

Despite these obvious global challenges, solutions appear to be on the decline. Whilst global patent applications for new antibiotics halved between 2004 and 2013, only 2 antibiotics NMEs were registered with the FDA between 2008 and 2012, down from 16 in the past 30 years.*

So what is jamming the infectious diseases drug development machine? Is it related to processes to detect and monitor pathogenic activities which may impact lab innovations especially on resistance activity? Could it be linked to the antibiotics/antiviral business models that don’t seem to be the most adapted to these new global challenges?

This Leadership Seminar will explore these questions with contributions from industry experts who are confronted by these challenges. This should appeal to any academic, biotech, pharma or investor who wants to make a contribution to the complex area that is infectious disease.

* These figures were taken from Peter Jackson, Executive Director of the AMR centre brilliant presentation at ON Helix 17. You can see it here.


09.30 – Registration over Tea and Coffee

10.00 – Welcome

Scene Setting

10.10 – Overview of Industry Activity and Deals
Christopher Berry, PharmaVentures

10.30 – Keynote Speaker Presentation

 – Keynote Speaker Presentation

11.30 – Pathogen Detection
This session should see presentations from companies offering diagnostics solutions to international pathogen surveillance consortia. The aim is to discuss how to detect quicker and share information better for patient and population benefit but also in order to advance research for new treatments.

12.30 – Lunch

13.50 – Innovative Approach to Pathogen Resistance
This session will see presentations from companies who are working on improving solutions to anti-microbial resistance or major viral unmet medical needs.

Speakers include:
Rachel Harland, ReViral
Fiona Marston, ABsynth Biologics

15.10 – Break

15.40 – Business Models of Infectious Disease
This session will highlight the misalignment between public health’s emphasis on Infectious Disease compared to challenges faced by companies to deliver drugs to patients and will present solutions on collaborative research or investment models.

Speakers include:
David Williams, Discuva
Alexis Rideau, Bioaster
Pete Jackson, The AMR Centre
Heather Shane, CARB-X

 – Closing Remarks

17.05 – Networking over Drinks

– Close

Event details

Location:Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL
Time & Date: 9.30am – 6.30pm, Wednesday 15th November
Admission: Please register online here.